Adzenys Xr-odt Tablet, Orally Disintegrating
NDC Package 70165-005-30
Package Information
Adzenys Xr-odt (amphetamine) tablets is a medication used to treat attention deficit hyperactivity disorder - ADHD. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Neos Therapeutics Brands, Llc, this product is identified by NDC 70165-005 and is authorized under FDA application NDA204326.
Identification & Billing
- RxCUI: 1739803 - amphetamine 12.5 MG 24HR Extended Release Distintegrating Oral Tablet
- RxCUI: 1739803 - 24 HR amphetamine 12.5 MG Extended Release Oral Tablet
- RxCUI: 1739803 - amphetamine 12.5 MG 24 HR Extended Release Distintegrating Oral Tablet
- RxCUI: 1739809 - Adzenys XR-ODT 12.5 MG 24HR Extended Release Distintegrating Oral Tablet
- RxCUI: 1739809 - 24 HR amphetamine 12.5 MG Extended Release Oral Tablet [Adzenys]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70165 - Neos Therapeutics Brands, Llc
- 70165-005 - Adzenys Xr-odt
- 70165-005-30 - 30 BLISTER PACK in 1 CARTON / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
- 70165-005 - Adzenys Xr-odt
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70165-005-30 identifies a specific commercial package of 30 blister pack in 1 carton / 6 tablet, orally disintegrating in 1 blister pack of Adzenys Xr-odt, a human prescription drug labeled by Neos Therapeutics Brands, Llc. This tablet, orally disintegrating is formulated for oral use and contains amphetamine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Neos Therapeutics Brands, Llc on February 16, 2016. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills.
How is this Neos Therapeutics Brands, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70165000530. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.